Obesity is a significant public health concern in the G7 countries and is growing as an epidemic. The body of evidence highlighting the physical and economic impact of obesity on society is…
The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug…
We expect the ulcerative colitis (UC) market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio,…
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…
China has the highest incidence of gastroesophageal cancer in the world. Chemotherapy is the main treatment, although targeted therapies such as trastuzumab (an anti-HER2 MAb for HER2-positive…
Two types of pharmacotherapy are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies (e.g., a SABA such as Teva’s ProAir HFA) that treat the…
Breast cancer is the most prevalent malignancy in women in China. Chemotherapy was the mainstay of treatment, but China now has access to several cutting-edge premium-priced targeted therapies (e.g…
Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Targeted therapies aimed at CDK4/6 inhibition (Pfizer’s Ibrance, Novartis’s Kisqali,…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MN patient populations, covering 171 countries and more than 99% of…
Clarivate Epidemiology's coverage of membranous nephropathy comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…